Clinical Trial Search

Primary: Incidence of Pre-dialysis HK After the LIDP in <3K Dialysate Patients — 50; 37 Percent of participants

Primary: HYP Attack Rate — 0.9; 4.8 attacks per week

Primary: Efficacy of Patiromer in Reducing Serum Potassium — 6.17; 6.6; 5.9; 6.47 mEq/L

Primary: Change in Glucose Tolerance as Measured by Area-under-the-curve — 328; 1000 AUC - mg*min/dL — p=0.5582

Primary: Change in Fasting Plasma Glucose From Week 4 to Week 16 — -5.6; 2.3 mg/dL

Primary: Adverse Events of Participants Taking Patiromer in Lowering Serum Potassium Levels in End Stage Renal Disease (ESRD) Patients With Hyperkalemia Measured by…

Primary: Plasma Potassium — 4.0; 4.0; 4.1; 3.7 mmol/l — p=0.007

Primary: Changes in Serum K+ Levels From Baseline — 0.029; 0.127 Milliequivalents Per Liter (mEq/l) — p=< 0.001

Primary: Exponential Rate of Change in Serum Potassium (S-K) Levels During the Initial 48 Hours of Study Drug Treatment. — -0.00128; -0.00187; -0.00205; -0.00280 log(mmol/L)/hour

Primary: Change From Baseline in Serum Potassium to the End of the 28-day Treatment Period. — -0.21; 0.23 mEq/L — p=< 0.001

Primary: 24-hour Average Systolic Blood Pressure — 127; 127; 126; 129 mmHg — p=0.07

Primary: Percentage of Participants With Serum Potassium in the Range of 3.5 - 5.5 mEq/L at the End of Treatment — 90.5 percentage of participants

Primary: Difference in the Exponential Rate of Change in Serum Potassium (S-K) Levels Versus Placebo During the Initial 48 Hours of Study Drug Treatment — 0; -0.00035; -0.00169…

Primary: Change in Serum Potassium From Part A Baseline to Part A Week 4 — -1.01 mEq/L — p=<0.001

Primary: Percentage of Subjects With Serum Potassium in the Target Range (3.8 - 5.0 mEq/L) at Either Week 3 or Week 4 — 82.5; 87.3 percentage of participants

Primary: Urinary-N-telopeptide — 47.2; 51.6; 44.5; 47 nml BCE/nmol creatinine

Primary: Number of Participants Remaining on Spironolactone at Week 12 — 126; 98 Participants — p=<0.0001

Primary: Mean Absolute Change in S-K From Baseline Until 4h After Start of Dosing With SZC/Placebo — -0.41; -0.27 mmol/L

Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg

Primary: Mean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population). — 5.0603; 4.7544; 4.5081; 4.3742 mmol/L

Primary: Least Square Mean S-K Level on Days 8-29 — 4.811; 4.381; 5.321 mmol/L — p=<0.001

Primary: Participants Who Achieved Response, Defined as Serum Potassium (sK+) Within 3.5 to 5.0 mEq/L, Spironolactone Greater Than or Equal to 25 mg Daily, no Rescue Therapy for…

Primary: Change in Fasting Serum Potassium Concentrations — -0.2 mg/dL

Primary: 24-hour Average Systolic Blood Pressure — 127; 127; 126; 129 mmHg

Primary: Least Square Mean S-K Level on Days 8-29 — 4.859; 4.440; 5.225 mmol/L — p=<0.001

Primary: Changes in Serum Level of Carboxyterminal Cross-linked Telopeptide of Type I Collagen (CTX); Over Time, i.e. Baseline, 3 Months, 6 Months. — 0.64; 0.64; 0.63; 0.56 µg/L…

Primary: Total Number of Episodes of Serum Potassium ≥ 5.5 mEq/L — 13; 41 episodes — p=0.024

Primary: Biochemical Markers of Bone Turnover — -6.25; -3.36; -0.14; 0.5 nmol/mmol

Primary: Percentage of Responders — 41.2; 1.0 Percentage of participants — p=<0.001

Primary: Least Squares Mean Change in Serum Potassium From Baseline to Week 4 or Time of First Titration for Each Individual Starting Dose Group — -0.35; -0.51; -0.55; -0.87…